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Abstract
A series of five mono-styryl and their corresponding symmetric di-styryl-2,6-diiodo-BODIPYs 
containing indolyl, pyrrolyl, thienyl or tri(ethylene glycol)phenyl groups were synthesized using 
Knoevenagel condensations. The yields for the condensation reactions were improved up to 40% 
using microwave irradiation (90 °C for 1 h at 400 W) due to lower decomposition of BODIPYs 
upon prolonged heating. The spectroscopic, structural (including the X-ray of a di-styryl-2,6-
diiodo-BODOPY) and in vitro properties of the BODIPYs were investigated. The extension of π-
conjugation through the 3,5-dimethyls of the known phototoxic 2,6-diiodo-BODIPY 1 produced 
bathochromic shifts in the absorption and emission spectra, in the order of 59–125 nm for the 
mono-styryl- and 126–220 nm for the di-styryl-BODIPYs in DMSO. The largest red-shifts were 
observed for the indolyl-containing BODIPYs while the largest fluorescence quantum yields were 
observed for the tri(ethyleneglycol)phenylstyryl-BODIPYs. Among this series, only the mono-
styryl-BODIPYs were phototoxic (IC50 = 2–15 µM at 1.5 J/cm2), and were observed to localize 
preferentially in the cell ER and mitochondria. On the other hand, the di-styryl-BODIPYs were 
found to have low or no phototoxicity (IC50 > 100 µM at 1.5 J/cm2). Among this series of 
compounds BODIPY 2a shows the most promise for application as photosensitizer in PDT.
Keywords
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1. Introduction
The investigation of BODIPY (difluoro boron dipyrromethene)-based bioimaging agents has 
been an active area of research in recent decades, that has produced a multitude of 
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fluorescent dyes with a variety of purposes including use as labels for biomolecules such as 
DNA, peptides, and lipids[1–4], as well as for applications as enzyme substrate fluorescent 
tags[5,6], as environmental indicators (pH and ion sensors)[7–10], and as cellular stains 
[11]. Despite their extensive investigation, only a few studies have evaluated BODIPYs for 
applications as photodynamic therapy (PDT) photosensitizers and as radioimaging agents, 
particularly for positron emission tomography (PET) and single photon emission computed 
tomography (SPECT). PDT is an effective and FDA-approved treatment for several forms of 
cancer and the age-related macular degeneration, using a porphyrin derivative as the 
photosensitizer. PDT is a tri-modal cancer therapy that combines a photosensitizer, light, 
and oxygen to generate reactive oxygen species (ROS), including singlet oxygen (1O2), that 
cause cell death [12,13]. PDT has many benefits over other therapies, including limited 
long-term side effects, relatively short treatment times, and the option for multiple 
treatments to be administered, due to its non-invasive nature and limited area of exposure 
[14–16]. Effective photosensitizers possess properties favoring singlet oxygen generation, 
including high quantum yields of photosensitizer triplet state (ΦT > 0.4), long triplet state 
lifetimes (τT ∼ 1 µs) and energy (ET ≥ 95 kJ mol−1), for efficient energy transfer to triplet 
molecular oxygen. In addition, low dark cytotoxicity, high photostability, and high 
absorption coefficients in the near-IR range (630 nm-800 nm) are desirable, since they allow 
for the use of long wavelength light with reduced tissue autofluorescence and scattering, and 
increased tissue penetration [17]. Current PDT anticancer agent Photofrin® (Pinnacle 
Biologics, Inc.) is FDA-approved for the treatment of melanoma, esophageal, digestive tract, 
genitourinary tract, and lung cancers. Although effective, Photofrin® has some drawbacks in 
that it absorbs only weakly in the red region of the spectrum, and is a mixture of compounds 
(porphyrin monomers and oligomers) with prolonged retention times in tissues, which 
causes patient photosensitivity for several weeks post-PDT [18]. In order to broaden the 
scope of PDT, development of photosensitizers with increased extinction coefficient within 
the therapeutic window, and high photodynamic activity are being actively explored.
BODIPY dyes have recently been shown to have potential application as PDT 
photosensitizers [19,20]. Their remarkable photophysical properties, including high 
extinction coefficients, easily tunable absorption and emission profiles, high stability and 
solubility, as well as their known ability to permeate cells, make them suitable for 
exploration as PDT agents [21,22]. It has been shown that some BODIPYs bearing heavy 
atoms, such as iodine or bromine, display cytotoxic properties when exposed to light while 
others remain non-toxic [23–29]. The effects of the “spin-orbit couplings” of heavy atoms 
favor intersystem crossing from the excited singlet to the triplet state needed for singlet 
oxygen generation [30–32]. Studies have shown that incorporation of iodines at the 2,6-
positions of BODIPYs leads to enhanced intersystem crossing, whereas addition at the 3,5-
positions promotes fluorescence [30]. In addition, phototoxicity depends on the substituents 
on the 2,6-diiodo-BODIPYs, and is favored by electron-donating 8-aryl groups [23–26].
The discovery of non-toxic halogenated BODIPYs, specifically those bearing iodines and 
fluorines, can lead to the development of multi-mode bioimaging agents for PET and 
SPECT, in addition to fluorescence imaging, with the incorporation of radioisotopes of 
iodine and fluorine. Nuclear imaging allows for the translation of the pathophysiological 
status of the tissues being imaged without interference. PET and SPECT are non-invasive 
Gibbs et al. Page 2













3D nuclear imaging techniques that allow for the mapping of a radiotracer’s uptake in vivo 
[33]. PET most commonly utilizes 18F-labeled radiopharmaceuticals (t1/2 = 109 minutes) 
and a 18F-labelled glucose derivative has shown to have great success in clinical imaging. 
Only a handful of reports have been published detailing the evaluation of 18F-bearing 
BODIPYs for PET/fluorescence dual modality imaging [34–36]. The 120I and 124I 
radioisotopes (t1/2 = 81 minutes and 4.18 days, respectively) also possess favorable PET 
qualities [33,37]. However, their low positron emission abundance, high positron energies, 
and lengthy synthetic protocols have hindered their widespread application in routine PET 
imaging. On the other hand, 123I and 131I (t1/2 = 13.2 hours and 8.05 days, respectively) 
have found significant importance as SPECT radiotracers for long term in vitro studies and 
radioimmunoassays. Many SPECT radiotracers are FDA-approved and currently used in 
clinical diagnostics. SPECT imaging is highly favored due to its ability to image 
endogenous peptides and antibodies, and due to the relatively long half-life of these 
isotopes, provides a means for measuring the slow kinetic processes of these ligands. To 
date, no studies on the synthesis and evaluation of radioiodine-labelled BODIPYs as SPECT 
radiotracers have been published. Ideal radiopharmaceuticals should possess characteristics 
that provide detectable diagnostic particles with minimal biological effect to cells or tissues, 
including relatively short half-life, suitable radionucleotide emissions of desired energy, 
high target uptake with high target-to-normal tissue ratio, efficient clearance from blood and 
non-target tissues while persisting in target for effective image contrast, and be inexpensive 
and easy to produce.
We have recently reported the synthesis and cytotoxicity properties of near-IR mono-and di-
indolylstyryl-BODIPYs [38], and a series of 2,6-diiodo-BODIPYs [26]. Among these, the 
mono- indolylstyryl-BODIPYs showed high uptake by HEp2 cells with no detectable 
cytotoxicity in the absence or presense of light, while the 8-(3,5-dimethyoxyphenyl)-2,6-
diiodo-1,3,5,7-tetramethyl-BODIPY (1) showed high phototoxicity (IC50 = 4 µM at 1.5 
J/cm2) but remained non-toxic in the dark (IC50 > 400 µM). Herein we report the synthesis 
of near-IR derivatives of BODIPY 1 by extension of the π-conjugation via Knoevenagel 
condensations on the 3,5-methyl groups, and the evaluation of their photophysical and in 
vitro properties. Our results show that the mono-styryl-2,6-diiodo-BODIPYs show promise 
for application as PDT photosensitizers, while the di-styryl-2,6-diiodo-BODIPYs display 
low cytotoxicity and may find applications as multi-mode near-IR fluorescent, PET and/or 
SPECT imaging probes.
2. Materials and Methods
2.1 Synthesis and characterization
2.1.1. General—Reagents and solvents were acquired from Sigma Aldrich and used 
without further purification. Reactions were monitored by TLC using 0.2 mm silica plates 
with UV indicator (UV254). Column chromatography was executed using Sorbent 
Technologies 60Ȧ silica gel (230–400 mesh) or Merck neutral aluminum oxide (70–230 
mesh). Merck TLC silica gel 60 glass plates were use for preparative thin layer 
chromatography. All 1H NMR and 13C NMR spectra were obtained using a Bruker AV-500, 
DPX-400, AV-400, or DPX-250 spectrometer (500 MHz, 400 MHz or 250 MHz for 1H, 100 
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MHz for 13C) with samples dissolved in deuterated chloroform, acetone, or DMSO using 
trimethylsilane as an internal indicator. Chemical shifts (δ) are conveyed in ppm with CDCl3 
(1H: 7.27 ppm; 13C: 77.16 ppm), acetone-d6 (1H: 2.05 ppm; 13C: 29.84 ppm), and DMSO-
d6 (1H: 2.50 ppm; 13C: 39.52 ppm) used as references. Coupling constants (J) are stated in 
Hertz (Hz). High resolution ESI mass spectra were obtained using an Agilent Technologies 
6210 ESI-TOF Mass Spectrometer.
2.1.2. BODIPYs 2a and 3a—BODIPY 1 (0.05 g, 0.08 mmol), indole-3-carbaldehyde 
(0.06 g, 0.4 mmol), and AcOH (0.4 mL) were dissolved in dry toluene over 4 Å molecular 
sieves (20 µM). To this solution was added piperidine (0.4 mL) and the mixture was stirred 
under 400 W microwave radiation at 90°C for 1 h. Upon cooling, the reaction was filtered to 
remove the sieves and the filtrate was quenched with water and extracted with CH2Cl2. The 
combined organic layers were dried over Na2SO4 and the solvent was removed under 
vacuum. The resulting residue was purified by silica column chromatography using 25% 
hexanes in CH2Cl2 (v/v) to 100% CH2Cl2 to afford 0.0225 g of a blue solid, 2a, in 38% 
yield and 0.028 g of a green solid, 3a, in 40% yield. Data For2a: mp = 175°C 
(decomposes); 1H-NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.51-8.47 (d, J = 16.9, 1H), 
8.13-8.11 (d, J = 7.3, 1H), 7.76-7.72 (d, J = 16.6, 1H), 7.56 (s, 1H), 7.41-7.39 (d, J = 7.1, 
1H), 7.31-7.27 (m, 2H), 6.60-6.58 (t, J = 2, 1H), 6.46-6.45 (d, J = 2, 2H), 3.19 (s, 6H), 2.71 
(s, 3H), 1.64 (s, 3H), 1.57 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.82, 154.95, 152.16, 
146.56, 143.39, 138.51, 137.07, 136.84, 133.86, 127.27, 125.56, 123.25, 121.56, 120.68, 
116.16, 115.07, 111.61, 106.21, 101.43, 69.55, 55.63, 53.80, 31.74, 29.28, 17.42, 16.72, 
16.09; MS (ESI-TOF) m/z calcd for C30H26BF2I2N3O2: 763.0175; Found: [M]+: 763.0186. 
Data for3a: mp = 195°C (decomposes); 1H-NMR (400 MHz, CDCl3) δ 8.53-8.48 (d, J = 
16.9, 2H), 8.47 (s, 2H), 8.21-8.19 (d, J = 7.3, 2H), 7.89-7.84 (d, J = 16.6, 2H), 7.56 (s, 2H), 
7.43-7.41 (d, J = 7.1, 2H), 7.30-7.24 (m, 4H), 6.61-6.60 (t, J = 2, 1H), 6.51-6.50 (d, J = 2, 
2H), 3.83 (s, 6H), 2.64 (s, 3H), 1.65 (s, 6H); 13C-NMR (100 MHz, CDCl3) 167.71, 161.75, 
137.13, 132.92, 132.33, 130.91, 128.83, 127.14, 125.54, 125.03, 125.14, 121.64, 120.89, 
116.45, 115.65, 111.55, 106.64, 101.45, 55.64, 17.27; MS (ESI-TOF) m/z calcd for 
C39H31BF2I2N4O2: 890.0598; Found: [M]+: 890.0639.
2.1.3. BODIPYs 2b and 3b—BODIPY 1 (0.05 g, 0.08 mmol), aldehyde 8 (0.11 g, 0.4 
mmol), and AcOH (0.4 mL) were dissolved in dry toluene over 4 Å molecular sieves (20 
µM). To this solution was added piperidine (0.4 mL) and the mixture was stirred under 400 
W microwave radiation at 90°C for 60 minutes. Upon cooling, the reaction was filtered to 
remove the sieves and the filtrate was quenched with water and extracted with CH2Cl2. The 
combined organic layers were dried over Na2SO4 and the solvent was removed under 
vacuum. The resulting residue was purified by silica column chromatography using 25% 
ethyl acetate in CH2Cl2 (v/v) to afford 0.028 g of a blue solid, 2b, in 40% yield and 0.030 g 
of a green solid, 3b, in 26% yield. Data for2b: mp = 63–65°C; 1H–NMR (400 MHz, 
CDCl3) δ 8.15-8.11 (d, J = 16.9, 1H), 7.60-7.57 (d, J = 8.6, 2H), 7.57-7.52 (d, J = 16.6, 1H), 
6.96-6.94 (d, J = 8.3, 1H), 6.60-6.59 (t, J = 2, 1H), 6.45-6.44 (d, J = 2, 2H), 4.20-4.18 (t, J = 
4.5, 2H), 3.90-3.88 (t, J = 4.6, 2H), 3.83-3.80 (s, 3H), 3.76-3.71 (m, 2H), 3.69-3.66 (m, 4H), 
3.58-3.56 (t, J = 4, 2H), 3.41 (s, 3H), 2.70 (s, 3H), 1.64 (s, 3H), 1.59 (s, 3H); 13C-NMR (100 
MHz, CDCl3) δ 161.89, 159.96, 156.72, 150.73, 146.17, 144.86, 139.64, 139.04, 136.57, 
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131.97, 131.51, 129.63, 129.15, 116.59, 114.87, 106.02, 101.46, 85.98, 82.19, 71.95, 70.89, 
70.67, 70.59, 69.68, 67.55, 59.06, 55.63, 17.31, 16.87, 16.17; MS (ESI-TOF) m/z calcd for 
C35H39BF2I2N2NaO6: 909.0856; Found: [M+Na]+: 909.0847. Data for3b: mp = 131–
134°C; 1H–NMR (400 MHz, CDCl3) δ 8.16-8.12 (d, J = 16.6, 2H), 7.61-7.57 (d, J = 8.6, 
4H), 7.59-7.57 (d, J = 16.6, 2H), 6.98-6.96 (d, J = 8.6, 4H), 6.61-6.60 (t, J = 2, 1H), 
6.46-6.45 (d, J = 2, 2H), 4.21-4.18 (t, J = 4.5, 4H), 3.91-3.88 (t, J = 4.6, 4H), 3.82 (s, 6H), 
3.78-7.75 (m, 4H), 3.72-3.66 (m, 8H), 3.58-3.55 (t, J = 4, 4H), 3.39 (s, 6H), 1.62 (s, 
6H); 13C-NMR (100 MHz, CDCl3) δ 161.86, 159.97, 150.53, 145.68, 139.12, 138.04, 
136.86, 132.52, 129.71, 129.25, 128.82, 116.76, 114.97, 114.30, 106.31, 101.45, 71.94, 
70.88, 70.67, 70.59, 69.69, 67.56, 59.07, 55.63, 17.35; MS (ESI-TOF) m/z calcd for 
C49H57BF2I2N2NaO10: 1159.2062; Found: [M+Na]+: 1159.2065.
2.1.4. BODIPYs 2c and 3c—BODIPY 1 (0.02 g, 0.03 mmol), thiophene-2-
carboxaldehyde (0.0035 g, 0.03 mmol), and p-TsOH (0.0025 g) were dissolved in dry 
toluene over 4 Å molecular sieves (5 µM). To this solution was added piperidine (0.1 mL) 
and the mixture was stirred at reflux for 4 hours. Upon cooling, the reaction was filtered to 
remove the sieves and the filtrate was quenched with water and extracted with CH2Cl2. The 
combined organic layers were dried over Na2SO4 and the solvent was removed under 
vacuum. The resulting residue was purified by careful silica preparatory plate 
chromatography using 1:1 DCM/hexanes (v/v) to afford 0.0048 g of a blue solid, 2c, in 19% 
yield and 0.0064 g of a green solid, 3c, in 25% yield. Data for2c: mp = 165°C 
(decomposes); 1H–NMR (400 MHz, CDCl3) δ 8.29-8.26 (d, J = 16.2, 1H), 7.47-7.44 (d, J = 
16.2, 1H), 7.37-7.36 (d, J = 5.2, 1H), 7.30-7.29 (d, J = 3.4, 1H), 7.08-7.07 (dxd, J = 3.8, 1.2, 
1H), 6.60-6.59 (t, J = 2, 1H), 6.44-6.43 (d, J = 2, 2H), 3.81 (s, 3H), 2.70 (s, 3H), 1.61 (s, 
3H), 1.58 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.91, 157.51, 149.64, 145.80, 145.78, 
142.57, 139.77, 136.49, 131.81, 128.85, 128.06, 127.30, 117.99, 105.98, 101.47, 55.62, 
17.23, 16.91, 16.23; MS (ESI-TOF) m/z calcd for C26H23BF2I2N2O2S: 729.9631; Found: 
[M]+: 729.9656. Data for3c: mp = 170°C (decomposes); 1H–NMR (500 MHz, CDCl3) δ 
8.33-8.30 (d, J = 16.2, 2H), 7.53-7.50 (d, J = 16.5, 2H), 7.40-7.39 (d, J = 4.9, 2H), 7.33-7.32 
(d, J = 3.4, 2H), 7.10-7.08 (dxd, J = 4, 2H), 6.61-6.60 (t, J = 2, 1H), 6.46-6.45 (d, J = 2, 2H), 
3.82 (s, 6H), 1.62 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 161.90, 149.95, 145.76, 142.66, 
136.74, 132.97, 132.23, 129.01, 128.13, 127.55, 118.06, 113.93, 106.27, 101.51, 83.62, 
55.64, 17.33; MS (ESI-TOF) m/z calcd for C31H25BF2I2N2O2S2: 823.9508; Found: [M]+: 
823.9512.
2.1.5. BODIPYs 2d and 3d—BODIPY 1 (0.04 g, 0.063 mmol), 5-nitroindole-3-
carboxaldehyde (0.06 g, 0.315 mmol), and p-TsOH (0.005 g) were dissolved in dry toluene 
20 mL. To this solution was added piperidine (0.4 mL) and the mixture was stirred under 
nitrogen at 60°C for 6.5 hours. Upon cooling, the reaction was quenched with water and 
extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and the 
solvent was removed under vacuum. The resulting residue was purified by silica column 
chromatography using CH2Cl2 to 10% EtOAc/ CH2Cl2 (v/v) to afford 0.0095 g of a blue 
solid, 2d, in 15% yield and 0.0136 g of a green solid, 3d, in 22% yield. Data for2d: mp = 
140°C (decomposes); 1H-NMR (400 MHz, CDCl3) δ 9.07 (s, 1H), 8.82 (s, 1H), 8.41-8.38 
(d, J = 16.8, 1H), 8.21-8.20 (d, J = 8.9, 1H), 7.80-7.77 (d, J = 16.8, 2H), 7.74 (s, 1H), 
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7.49-7.47 (d, J = 9.2, 1H), 6.63-6.62 (t, J = 2, 1H), 6.48-6.47 (d, J = 2, 2H), 3.84 (s, 3H), 
2.76 (s, 3H), 2.20 (s, 3H), 1.67 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.92, 157.17, 
154.77, 145.03, 142.92, 139.64, 136.55, 130.26, 128.84, 127.99, 127.22, 125.22, 118.72, 
118.31, 118.14, 118.02, 117.78, 117.63, 111.57, 106.05, 101.48, 55.64, 17.23, 16.89, 16.19; 
MS (ESI-TOF) m/z calcd for C30H25BF2I2N4O4: 808.0026; Found: [M]+: 808.0020. Data 
for3d: mp = 170°C (decomposes); 1H-NMR (500 MHz, DMSO-d6) δ 12.45 (s, 2H), 8.91 (s, 
2H), 8.53-8.49 (d, J = 16.8, 2H), 8.16 (s, 2H), 8.09-8.06 (d, J = 8.9, 2H), 7.79-7.76 (d, J = 
16.8, 2H), 7.67-7.65 (d, J = 8.9, 2H), 6.68 (s, 3H), 3.80 (s, 6H), 2.08 (s, 6H); 13C-NMR (100 
MHz, DMSO-d6) δ 161.95, 150.09, 147.42, 145.55, 142.27, 141.02, 137.51, 136.75, 133.05, 
132.63, 132.15, 124.66, 118.29, 116.96, 116.49, 115.79, 113.45, 106.65, 56.09, 17.24; MS 
(ESI-TOF) m/z calcd for C39H29BF2I2N6O6: 980.0299; Found: [M]+: 980.0327.
2.1.6. BODIPYs 2e and 3e—BODIPY 1 (0.04 g, 0.063 mmol), ethyl 4-formyl-3,5-
dimethylpyrrole-2-carboxylate (0.061 g, 0.315 mmol), and p-TsOH (0.005 g) were dissolved 
in dry toluene (20 mL) over 4 Å molecular sieves. To this solution was added piperidine (0.4 
mL) and the mixture was stirred under nitrogen at 60°C for 48 hours. Upon cooling, the 
reaction was filtered to remove the sieves and the filtrate was quenched with water and 
extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and the 
solvent was removed under vacuum. The resulting residue was purified by silica preparatory 
plate chromatography using CH2Cl2 to 5% EtOAc/ CH2Cl2 (v/v) to afford 0.0098 g of a 
blue solid, 2e, in 19% yield and 0.024g of a green solid, 3e, in 39% yield. Data for2e: mp = 
160°C (decomposes); 1H–NMR (500 MHz, CDCl3) δ 8.90 (br s, 1H), 8.25-8.22 (d, J = 16.9, 
1H), 7.39-7.36 (d, J = 17.1, 2H), 6.59-6.58 (t, J = 2, 1H), 6.44-6.43 (d, J = 2, 2H), 4.37-4.33 
(q, J = 6.9, 2H), 3.81 (s, 3H), 2.65 (s, 3H), 2.56 (s, 3H), 2.54 (s, 3H), 1.62 (s, 3H), 1.56 (s, 
3H), 1.41-1.38 (t, J = 7, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.84, 161.58, 155.49, 
151.94, 146.50, 143.81, 138.94, 136.74, 133.99, 133.28, 131.96, 131.12, 128.26, 120.25, 
118.21, 116.16, 106.14, 101.40, 85.32, 81.84, 60.12, 55.61, 17.34, 16.75, 16.05, 14.52, 
13.67, 11.47; MS (ESI-TOF) m/z calcd for C31H32BF2I2N3O4: 813.0543; Found: [M]+: 
813.0538. Data for3e: mp = 150°C (decomposes); 1H-NMR (500 MHz, acetone-d6) δ 10.83 
(br s, 2H), 8.38-8.34 (d, J = 16.9, 2H), 7.59-7.54 (d, J = 16.9, 2H), 6.71 (s, 3H), 4.31-4.25 (q, 
J = 6.9, 4H), 3.89 (s, 6H), 2.81 (s, 3H), 2.77 (s, 3H), 2.60 (s, 3H), 1.65 (s, 6H), 1.35-1.29 (t, 
J = 7, 3H); 13C-NMR (100 MHz, acetone-d6) δ 162.13, 160.64, 134.68, 132.43, 127.58, 
127.15, 119.71, 118.54, 115.85, 113.88, 106.28, 101.72, 76.34, 59.32, 55.20, 54.58, 48.21, 
16.44, 13.92, 12.18, 12.13, 10.92; MS (ESI-TOF) m/z calcd for C41H43BF2I2N4NaO6: 
1013.1231; Found: [M+Na]+: 1013.1217.
2.1.7. Crystal data—Diffraction data were collected at 100 K on a Bruker Kappa Apex-II 
DUO diffractometer equipped with MoKa radiation (λ = 0.71073 Å). Refinement was by 
full-matrix least squares using SHELXL, with H atoms in idealized positions. Compound 3b 
has four independent molecules and large displacement parameters for its polyether chains. 
Isotropic atoms with heavily restrained refinement was necessary in these regions, and some 
disorder in the polyethers could not be modeled. Crystal data: For 1: C21H21BF2I2N2O2, 
monoclinic P21/c, a=7.0702(3), b=16.8644(7), c=18.4079(8) Å, β=92.838(2)°, Z=4, 
T=100K, θmax=40.34°, R=0.026 for 11738 data with I>2σ(I) (of 13815 unique), 277 
parameters; For 3b: C49H57BF2I2N2O10, triclinic P1, a = 12.2712(5), b = 19.5190(8), c = 
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22.4285(8) Å, α = 106.006(2), β = 101.516(2), γ = 104.576(2)°, Z = 4, T = 100 K, θmax = 
30.11°, R = 0.060 for 30040 data with I > 2σ(I) (of 48144 unique), 1953 parameters, 2097 
restraints. Cambridge Structural Database deposition numbers for the structures are CCDC 
983490–983491. Copies if the data can be obtained, free of charge, on application to CCDC, 
12 Union Road, Cambridge, CB2 1EZ, UK, (fax: +44-(0)1223–336033 or 
deposit@ccdc.cam.ac.uk).
2.1.8. Absorption and Fluorescence Spectroscopy—The spectroscopic properties 
of BODIPYs 1, 2a–e, and 3a–e were determined on solutions prepared by dissolving 
crystalline compound in dichloromethane, THF, or DMSO. Stock solutions (5×10−5 M) 
were prepared and diluted to appropriate concentrations for collection of absorbance and 
emission spectra. Absorption spectra were obtained on a Varian Cary 50 Bio UV/VIS 
Spectrophotometer. Measurements obtained for determining optical density were taken from 
solutions with concentrations between 1.2×10−5 and 5×10−5 M so that λ max was between 
0.5 and 1.0. Fluorescence measurements were recorded on solutions with concentrations 
between 1.2×10−6 and 2.5×10−5 M to attain an optical density at the excitation wavelength 
between 0.04 and 0.06 to minimize intermolecular reabsorption and inner-filter effects. 
Compounds were excited at 485 nm for 1, 530 nm for 2a, 2c, 2d, and 2e, 535 nm for 2b, 660 
nm for 3a, 580 nm for 3b, 600 nm for 3c, 635 nm for 3d and 630 nm for 3e. Emission 
spectra were acquired on a PTI QuantaMaster4/2006SE spectrofluorometer with the slit 
width set at 3 nm for dichloromethane and THF and 5 nm for DMSO. Rhodamine 6G and 
methylene blue were used as standards in calculating the fluorescence quantum yields (Φf = 
0.95 in ethanol and Φf = 0.03 in methanol, respectively). All measurements, both absorbance 
and emission, were acquired within 4 h of solution preparation at room temperature (23 – 25 
°C), using a 10 mm path length quartz spectrophotometric cell.
The dark and photostability of all BODIPYs were assessed by measuring the change in 
fluorescence when excited at a compound specific wavelength (485 nm for 1, 530 nm for 2a, 
2c, 2d, and 2e, 590 nm for 3a, 535 nm for 2b, 580 nm for 3b, 600 nm for 3c and 3e, and 610 
nm for 3d). Solutions of 25 µM BODIPY were made by dissolving crystalline BODIPY in 
DMSO and were used immediately. For dark studies, the vials containing BODIPY 
solutions were covered in aluminum foil to minimize light exposure. To assess potential 
photo-induced decomposition, the compounds were exposed to ambient light, by keeping the 
BODIPYs in 20 mL scintillation vials on the bench top under 32 W light from Sylvania 
OCTRON®/ECO® 4100K for a period up to 24 h.
2.2. Cellular studies
2.2.1. General—All reagents and tissue culture media were purchased from Invitrogen. 
The human carcinoma HEp2 and murine hepatoma 1c1c7 cells used for the studies were 
purchased from ATCC and were sustained at 37°C and 5% CO2 in a 50:50 mixture of 
DMEM:AMEM augmented with 10% FBS and 1% antibiotic (Penicillin-streptomycin). 
Working BODIPY stock solutions of 32 mM BODIPY was prepared by dissolving the 
compound with sonication in 96% DMSO and 4% Cremophor EL.
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2.2.2. Time-dependent cellular uptake—The HEp2 cells were grown overnight in a 
Costar 96-well plate plated at 15,000 cells per well. The 32 mM stock solution was diluted 
to a 10 µM BODIPY solution through the addition of medium containing 5% FBS and 1% 
antibiotic to a 400 µM stock solution. The cells were exposed to the BODIPY in medium 
solution at 100 µL/well at time intervals of 0, 1, 2, 4, 8, and 24 hours. At the termination of 
the treatment, the loading medium was removed and the cells were washed with 1X PBS, 
and solubilized by adding 0.25% Triton X-100 in 1X PBS. Quantification of the cells was 
conducted using the CyQuant Cell Proliferation Assay (Life Technologies). BODIPY 
concentration was determined by reading fluorescence at 355/670 nm or 410/700 nm with a 
FluoStar Optima micro-plate reader (BMG LRBTEH). Cellular uptake is expressed in nM 
compound/cell.
2.2.3. Dark Cytotoxicity—The HEp2 cells were placed in a 96-well plate as above and 
allowed to incubate overnight. Following incubation, the cells were exposed to increasing 
concentrations of BODIPY, from 0 µM up to 400 µM, and then incubated at 37°C. After 24 
hour incubation, the loading media containing compound was removed by washing the cells 
with 1X PBS. The media was replaced with media containing 20% Cell Titer Blue and the 
cells were incubated at 37°C for a subsequent 4 hours. Cell viability was determined by 
reading fluorescence at 570/615 nm with a FluoStar Optima micro-plate reader. The dark 
toxicity is expressed in terms of the percentage of viable cells.
2.2.4. Phototoxicity—The HEp2 cells were placed in 96-well plates as incubated as 
described above. Following incubation, the cells were exposed to increasing concentrations 
of BODIPY (0 µM, 3.125 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, and 100 µM) and then 
incubated for 24 hours at 37°C. After the 24 hour treatment, the loading media was 
removed, the cells were washed with 1X PBS and refilled with fresh media. The cells were 
then exposed to a 600 W halogen lamp light source fitted with a water filter (Newport) and a 
beam turning mirror 200 nm-3 µm (Newport) to generate an approximate light dose of 1.5 
J/cm2. After a 20 min exposure time, the cells were incubated for another 24 h. Following 
incubation, the medium was removed and replaced with medium containing 20% of Cell 
Titer Blue and the cells were incubated for a subsequent 4 hours. Cell viability was 
determined by reading fluorescence at 570/615 nm with a FluoStar Optima micro-plate 
reader. The phototoxicity is expressed in terms of the percentage of viable cells.
2.2.5. Subcellular localization—HEp2 cells were plated in a 6-well plate and allowed to 
grow overnight. The cells were then exposed to 10 µM of the compound at 37°C for more 
than 6 hours before adding the organelle tracer (Invitrogen). The working concentrations of 
organelle tracers were as following: LysoSensor Green 50 nM, MitoTracker Green 250 nM, 
ER Tracker Blue/white 100 nM, and BODIPY FL C5 Ceramide 50 nM. The organelle 
tracers were diluted in growing medium and the cells were incubated concurrently with the 
compound and the tracer for 30 minutes. After adding the tracer for 30 minutes, the loading 
medium is removed and cells were washed with 1X PBS three times. Images were acquired 
using a Leica DMRXA2 microscope with a water immersion objective and DAPI, GFP, 
Texas Red, and TRITC filter cubes (Chroma Technologies).
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2.2.6. ROS formation—For this study, murine hepatoma 1c1c7 cells (ATCC CRL-2026) 
were employed and maintained as previously described [39]. Murine hepatoma 1c1c7 cells 
were cultured on 22 mm glass coverslips. Formation of OH radical was assessed after 
incubation for 60 min at 37 °C in medium containing 10 µM concentrations of BODIPY 2a 
or 3a + 2 µM of APF ([6-(4’-amino)phenoxy-3H–xanthen-3-on-9-yl]benzoic acid) or DADB 
(diethyl-3-3’-(9,10-anthracenediyl)bis acrylate). The medium was then replaced and the 
cells were irradiated. The light source was a 600 W quartz-halogen lamp with IR radiation 
attenuated by a 10 cm layer of water and further limited by interference filters (±10 nm). 
The wavelengths employed were 630 nm (2a) or 725 nm (3a) at a light dose of 90 mJ/cm2. 
Fluorescence of APF was detected by fluorescence microscopy using 450 nm excitation and 
measuring emission at 525 nm. The signal increases as a function of •OH formation. In 
contrast, DADB fluorescence is decreased when the probe interacts with 1O2.
2.3. Comparative Singlet Oxygen Generation Studies
To each well of a 6-well plate was added 2 mL containing 50 µM of 1,3-
diphenylisobenzofuran (DPBF) and 5 µM of photosensitizers in DMSO. The plate was 
irradiated using a 71 W filtered light source of > 500 nm with a Schott glass 500 nm long-
pass yellow filter for 1 hour. At 15 min intervals, 200 µL aliquots were removed from each 
of the six wells and the absorbance was measured at 410 nm. The rate of singlet oxygen 
generation was determined by the decrease in absorbance of DPBF over time. A control 
solution of DPBF/methylene blue (reference standard) was irradiated under the above 
conditions. Absorption spectra were chronicled using a Varian Cary 50 Bio UV/VIS 
Spectrophotometer.
2.4. Octanol-HEPES buffer coefficients
The partition coefficients (log P) were measured at room temperature by adding 0.5 mL of a 
BODIPY stock solution in DMSO (50 µM) to a 15 mL volumetric tube containing 4.0 mL of 
HEPES buffer (1 M, pH 7.4), followed by addition of 4.0 mL of 1-octanol. After vortexing 
for 5 min, the phases were allowed to separate completely. An aliquot of 0.5 mL from each 
layer was diluted with 0.5 mL of methanol and the absorbance was read on an Agilent 
Technologies 8354 UV-Vis spectrophotometer with 10 mm path length quartz cuvette.
3. Results and discussion
3.1. Syntheses and structural characterization
We have recently reported the synthesis of BODIPY 1 via condensation of 2,4-
dimethylpyrrole with 3,5-dimethoxybenzaldehyde, followed by oxidation, boron 
complexation and iodination using iodic acid, in 33% overall yield (4 steps) [26]. In order to 
increase the solubility and the absorption and emission maxima of BODIPY 1 (λmax = 535 
and 549 nm, respectively, in dichloromethane), one or two styryl groups were introduced via 
Knoevenagel condensation of the 3,5-dimethyl groups with polar aromatic aldehydes, as 
shown in Scheme 1.
The Knoevenagel reaction in the presence of excess aromatic aldehyde afforded the mono- 
and di-styryl-BODIPYs 2a–e and 3a–e, respectively, in 15–40% yields [23–25,38]. The 
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reactions were performed in refluxing toluene, and molecular sieves were used to remove 
the water formed during the reaction. Since prolonged reflux led to significant 
decomposition of both starting materials and products [23–25,38], alternative reaction 
conditions were investigated to optimize product yields, including different reaction times, 
concentrations, equivalents of aryl aldehyde, temperatures, and microwave (400 W) 
radiation. The highest yields were obtained when the electron-rich indole-3-carbaldehyde 
and tri(ethyleneglycol)benzaldehyde 7 were used along with 400 W microwave irradiation at 
90 °C for 1 h. The microwave-assisted synthesis and functionalizations of BODIPYs have 
been previously investigated [40–42] and applied to Knoevenagle condensations [42]. This 
technique has the advantages of allowing shorter reaction times, producing high yields and 
low decomposition of products.
The aryl groups used to extend the π-conjugation of 1 were chosen to increase the styryl-
BODIPY solubility and cellular permeability, via insertion of a triethylene glycol or a 
heteroatom aromatic group, as we have recently explored [38]. The electron-withdrawing 
groups in 2d,e and 3d,e were introduced with the aim to increase the styryl-BODIPY’s 
stability. The synthesis of tri(ethyleneglycol)benzaldehyde 7 was carried out in 3 steps from 
4-hydroxybenzaldehyde, as previously reported (see Supporting Information). Protection of 
the aldehyde group to give 4, followed by reaction with tosyl tri(ethylene)glycol 
monomethyl ether 5, in the presence of K2CO3 in refluxing acetonitrile gave compound 6, 
which was deprotected using mercury perchlorate in THF affording 
tri(ethyleneglycol)benzaldehyde 7 [43] in 48% overall yield. The indole group was chosen 
to increase the wavelenghts of absorption and emission of the styryl-BODIPYs, and to 
enhance their biological efficacy due to its resemblance to the naturally occurring amino 
acid tryptophan, a key component in the structure of many enzymes and proteins, and a 
precursor of serotonin, melatonin, and niacin [44]. However, it was noted over the course of 
experimentation that BODIPYs 2a and 3a quickly decomposed (< 24 h) when left in 
solution or in crystalline form under ambient light (see Supporting Information, Figures S2 
and S3). For this reason, 5-nitroindole-3-carboxaldehyde, prepared according to the 
literature [45], was also used in the Knoevenagle condensation with 1 with the aim to 
enhance the stability of BODIPYs 2d and 3d relative to 2a and 3a. The addition of the nitro 
group did enhance the stability of the BODIPYs, although significant decomposition was 
still observed with time for the indolylstyryl- and the pyrrolylstyryl-BODIPYs 2a/3a, 2d/3d 
and 2e/3e. The most stable BODIPYs of this series were 2b/3b and 2c/3c. 1H–NMR 
investigations of 2d and 3d in DMSO-d6 upon exposure to ambient light for up to 12 days 
were also conducted (see Supporting Information, Figure S4). Both compounds were stable 
up to 1 day, however decomposition was observed after that, particularly for the di-
substituted BODIPY 3d. The integration of the NMR signals corresponding to the 
nitroindolylstyryl group of BODIPY 3d observed at 9.1 (NH), 8.8, 8.4, 8.2, 7.8, 7.7, and 7.5 
significantly decreased by day 12, while signals corresponding to the nitroindolyl group 
could be identified as time progressed.
The structures of all BODIPYs synthesized were confirmed by 1H- and 13C-NMR, HRMS, 
and UV/VIS and fluorescence spectroscopies. Single crystals of 12 and 3b suitable for X-ray 
analysis (see Figure 1) were grown from slow evaporation of acetone. The X-ray crystal 
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structures of 1 and 3b revealed the expected planarity of the BODIPY core that extended 
through the 2,6-diiodo groups. The C9BN2 ring system exhibited mean deviation of 0.013 Å 
for 1 and 0.011-0.035 Å for the four independent molecules of 3b. In both cases the iodine 
atoms lie less than 0.11 Å from these mean planes, and the methyl C atoms less than 0.06 Å. 
The meso-phenyl groups are roughly orthogonal to the core to reduce steric strain caused by 
the 1,7-dimethyls, forming dihedral angles of 79.97(2)° for 1 and 88.9(2)-90.0(2)° for the 
four independent molecules of 3b. The boron atom possesses tetrahedral geometry with the 
BF2 groups also lying perpendicular to the BODIPY core, forming dihedral angles of 
89.23(4)° for 1 and 87.7(9)-89.3(10)° for 3b. Short intermolecular B-F…π interactions are 
observed between one pair of independent molecules in the crystal of 3b. The distances 
between the F atoms of one molecule and the centroids of the central ring of the C9BN2 ring 
system of another molecule are 2.750 and 2.767 Å. The polyether chains of 3b are very 
flexible, and the eight independent chains exhibit a wide variation of conformations in the 
solid. In the 1H–NMR spectra in CDCl3, the ortho-phenyl hydrogens for all BODIPYs (see 
Supporting Information) appear as doublets at ∼ 6.5 ppm, while the para-hydrogens are 
triplets slightly shifted downfield at ∼ 6.6 ppm. The styryl groups double bonds have a trans 
(E) configuration in all BODIPYs, as indicated by the coupling constants of the alkene 
protons, between 16.2–17.1 Hz, and as also seen in Figure 1. Significant differences were 
seen in the chemical shifts of the 1,3,5,7-methyl groups. In the case of BODIPY 1 the 
methyls appear as two sets of equivalent protons, at 2.5 ppm for the 3,5-dimethyls and 1.5 
ppm for the 1,7-dimethyls due to shielding by the meso-aryl group. Addition of one styryl 
arm creates asymmetry in the BODIPYs causing the methyl groups to appear as singlets at 
2.7 ppm, 1.6 ppm and 1.5 ppm. The incorporation of the second styryl group restores 
symmetry and causes reappearance of a single signal for the 1,7-dimethyls at 1.6 ppm. Only 
slight changes in the chemical shifts of the styryl groups were observed in the 1H- and 13C-
NMR spectra of the mono- vs. di-styryl-BODIPYs. All spectra were recorded in deuterated 
chloroform, with exception of 3d and 3e, which was obtained in DMSO-d6 and acetone-d6, 
respectively, due to their decreased solubility in chloroform and dichloromethane.
3.2. Spectroscopic properties
The spectroscopic characteristics of the BODIPYs were explored in dichloromethane, THF, 
and DMSO and the results obtained are shown in Figure 2, Table 1 and the Supporting 
Information, Figure S1. Incorporation of one styryl group onto the BODIPY core, as in 2a–
e, induced pronounced red-shifts in the absorption (59 - 98 nm) and emission (59 - 125 nm) 
spectra, compared with BODIPY 1 in DMSO. Addition of a second styryl group induced 
even greater red-shifts of 126 - 189 nm and 129 - 220 nm for the absorption and emission, 
respectively, due to further extension of the π-conjugation. In addition, the absorption and 
emission bands become broader and more intense with increasing number of styryl 
substituents. All Q-band absorptions, due to the S0-S1(π-π*) electronic transition, show a 
shoulder at lower wavelength that is attributed to the vibrational transitions [42], and most 
pronounced for the styryl-BODIPYs, and in particular for BODIPY 3a in THF and 
dichloromethane solutions (Supporting Information, Figure S1). The broader and weaker 
2The authors acknowledge Dr. Gregory McCandless preliminary work on the crystal structure of BODIPY 1.
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absorption bands seen in the absorption spectra of the styryl-BODIPYs centered at 460 nm 
are likely due to the S0-S2 transition [42]. In DMSO the Q-band absorptions of all BODIPYs 
strictly follow the Lambert-Beer’s law (see Supporting Information, Figure S5), suggesting 
that there is no aggregation in this solvent. In addition, small to moderate red-shifts in λmax 
(1–25 nm) were observed for the BODIPYs in DMSO, compared to THF and 
dichloromethane, indicating that excitation of the BODIPYs leads to more polarized excited 
states that are stabilized by the more polar solvent [42]. All BODIPYs displayed absorption 
maxima within the PDT biological window, between ca. 600 and 770 nm in DMSO, with 
large extinction coefficients (log ε = 4.1–4.9). The Stokes shifts ranged from 219-1,053 
cm−1 with the greater enhancement observed for the mono-styryl BODIPYs.
The presence of the 2,6-diiodo groups in the BODIPYs is expected to cause red-shifts in the 
absorption and emission of the BODIPY core due to lower HOMO-LUMO gap [23,26] as 
well as decrease in fluorescence quantum yields due to enhanced intersystem crossing from 
the excited singlet to the triplet state because of spin-orbit coupling by the heavy atom 
effect. Interestingly, the extension of π-conjugation via incorporation of the styryl groups, 
enhanced the fluorescence quantum yields of styryl-BODIPY 2a–e and 3a,b,e compared 
with 1. This effect was more pronounced in BODIPYs 2b and 3b, bearing the triethylene 
glycol groups, maybe as a result of their enhanced aqueous solubility, despite the flexible 
chains [24,25,46]. Although the 2,6-iodines are expected to enhance production of singlet 
oxygen, the main cytotoxic species in PDT, we have recently shown that only a handful of 
2,6-diiodo-BODIPYs containing different meso-substituents, are phototoxic to HEp2 cells 
[26]. The comparative singlet oxygen quantum yields of the BODIPYs relative to methylene 
blue (ΦΔ = 0.52) were determined [26,32], and the results are shown in Table 2. In addition, 
the formation of singlet oxygen and hydroxyl radicals after irradiation of photosensitized 
cells was also determined [47] (vide infra).
3.3. Cellular Properties
The concentration-dependent dark and photo (light dose ∼ 1.5 J/cm2) cytotoxicities of all 
BODIPYs were investigated in human carcinoma HEp2 cells using the Cell Titer Blue 
assay, and the results are shown in Figures 3 and 4 and summarized in Table 2 (see also 
Supporting Information, Figure S6). None of the BODIPYs were toxic in the dark (IC50 > 
400 µM), with exception of BODIPY 2a, which showed low cytoxicity ( I C50 = 148 µM). 
Upon exposure to low light dose (∼ 1.5 J/cm2) all the mono-styryl-BODIPYs showed high 
phototoxicity with IC50 values between 2–15 µM, while the di-styryl-BODIPY were much 
less phototoxic with determined IC50 > 100 µM. It has been previously shown that the 
presence of electron-donating alkoxyphenyl substituents at the 8-position and two iodides or 
bromides at the 2,6-positions [23–26], as in BODIPY 1, induces high phototoxicity with no 
detectable dark cytotoxicity. It is interesting that in this series of compounds, the mono-
styryl BODIPYs retain the phototoxic properties of BODIPY 1 but the di-styryl BODIPYs 
do not, although the comparative singlet oxygen quantum yields determined using DPBF as 
acceptor [26,32] (see Table 2), suggest that all BODIPYs can produce singlet oxygen. The 
formation of singlet molecular oxygen (1O2) and hydroxyl radical (•OH) after irradiation of 
photosensitized cells was determined using murine hepatoma 1c1c7 cells and fluorescent 
probes APF and DADB, as previously described [47]. APF is a highly selective probe 
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for •OH [48] while DADB is a cell-permeable probe for 1O2 [49]. We have previously used 
these probes to assess ROS formation as a result of photodynamic processes [50]. The 
results shown in Figure 4 indicate that irradiation of 1c1c7 cells photosensitized by BODIPY 
2a results in formation of •OH but not 1O2. A similar treatment with 3a produced no 
detectable decrease in the fluorescence signal. While these are only qualitative results, they 
provide information on the ability of these agents to produce ROS in a cellular environment, 
and might explain the observed phototoxicity of the mono-styryl-BODIPYs in comparison 
with the di-styryl-BODIPY derivatives. Similar studies on HEp2 cells have not yet been 
carried out, but in our experience, there is little variation in ROS production as a function of 
cell type.
The high phototoxicity observed for the mono-styryl-BODIPYs might be due to their 
unsymmetric structure, which favors their cellular uptake and/or their binding to specific 
intracellular proteins. On the other hand, the symmetric structure of the di-styryl-BODIPYs 
induces low or no phototoxicity. Nevertheless, Akkaya et al. [23] and Ng et al. [24] reported 
several symmetric 3,5-distyryl-BODIPYs containing 2,6-diiodo or 2,6-dibromo substituents 
that were phototoxic to K562 and HT20 cells, respectively, at much higher light doses. The 
most phototoxic compound in these studies contained five triethylene glycol chains (IC50 = 
7 nM at 48 J/cm2) and its phototoxicity was attributed to its high cellular uptake and 
preferential localization in the cell ER. Unsymmetrical distyryl-2,6-diiodo-BODIPYs 
bearing three ethylene glycol groups and amine functionalities were also found to be 
phototoxic to HT29 cells (as low as IC50 = 15 nM at 48 J/cm2), due in part to their partial 
localization in cell mitochondria [25]. We recently reported [26] that the phototoxicity of 
2,6-diiodo-BODIPYs depends on the nature of the 8-substituent, and BODIPY 1 was among 
the most phototoxic (IC50 = 4 µM at 1.5 J/cm2) of a series of eleven 2,6-diiodo-BODIPYs 
investigated with varying 8-substituents. Extension of the π-conjugation of BODIPY 1 via 
introduction of one styryl group, as in 2a–e, still afforded highly phototoxic derivatives, 
while the introduction of a second styryl group, as in 3a–e, decreased phototoxicity and the 
ability for producing ROS in cells. We have also reported that mono- and distyryl-BODIPYs 
without the 2,6-diiodo groups show no phototoxicity to HEp2 cells [38]; the introduction of 
iodides at the 2,6-positions induces phototoxicity in the mono-styryl-BODIPYs but not on 
the di-styryl-BODIPYs. Our results suggest that while the phototoxic mono-styryl-
BODIPYs 2a–e are promising photosensitizers for PDT, particularly 2a (ε ∼ 29,000 
M−1.cm−1 at λmax636 nm, ΦΔ= 0.72), the di-styryl-BODIPYs of low dark and photo 
cytotoxicities, particularly 3b (λmaxemission at 697 nm, Φf = 0.44), are promising 
fluorophores for near-IR bioimaging.
To further investigate the cause of phototoxicity in this series of BODIPYs, the cellular 
uptake was evaluated over a period of 24 h, and the results from these studies are shown in 
Figures 5–11 (and Supporting Information, Figures S7–S11). All BODIPYs were quickly 
and efficiently internalized by cells, although the extent of their uptake did not correlate with 
their hydrophobic character, as determined by their partition coefficients (log P) [51] in 
octanol-HEPES buffer pH = 7.4, shown in Table 2. In general, higher hydrophobic character 
was observed with increasing number of styryl groups. BODIPYs 2b,e and 3a,d were taken 
up very quickly in the first 2 h, but after 24 h, BODIPYs 2a–c and 3d,e were found the most 
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within cells, while 2e accumulated the least. In all cases except for BODIPYs 2e and 3a, the 
amount of BODIPY taken up by the cells increased significantly from 8 to 24 h. Following 6 
h uptake into cells, the subcellular localization of the BODIPYs was investigated by 
fluorescence microscopy. Organelle-specific fluorophores BODIPY Ceramide (Golgi), 
LysoSensor Green (lysosomes), MitoTracker Green (mitochondria), and ER Tracker Blue/
White (ER) were used in the overlay experiments. The purple or yellow/orange colors 
indicate co-localization of BODIPY and organelle tracker. All BODIPYs localized in 
multiple organelles, including the lysosomes, Golgi, ER and the cell mitochondria. While 
the major sites of localization for the mono-styryl-BODIPYs were found to be the ER, 
lysosomes and mitochondria, the di-styryl-BODIPYs accumulated preferentially in the 
Golgi, and to a lower extent in the ER and mitochondria. This result, along with their ability 
for producing ROS in cells (see above), is responsible for the observed higher phototoxicity 
of the mono-styryl-diiodo-BODIPYs relative to their di-styryl analogs. Both the ER and 
mitochondria are important PDT targets, and accumulation of photosensitizer in these 
organelles can lead to rapid cell death due to photodamage to anti-apoptotic Bcl-2 proteins 
located in the ER and mitochondrial membranes, and/or by direct mitochondrial 
photodamage [52]. It is possible that the mono-styryl-diiodo-BODIPYs bind preferentially 
to anti-apoptotic Bcl-2 proteins compared with their di-styryl analogs, causing cell apoptosis 
and/or autophagy [53], leading to rapid cell death. Previous studies have also shown that 
phototoxic BODIPYs tend to localize preferentially in the ER or mitochondria [24–29].
4. Conclusions
A series of mono- and di-styryl-diiodo-BODIPYs with absorptions and emissions in the ca. 
600–770 nm region were synthesized via Knoevenagel condensations on a 2,6-diiodo-3,5-
dimethyl-BODIPY (1), in yields up to 40% upon microwave irradiation (90°C for 1h at 400 
W). Indolyl-, tri(ethyleneglycol)phenyl-, thienyl-, and pyrrolyl-containing styryl groups 
were introduced with the aim to red-shift the absorption and emission profiles of phototoxic 
BODIPY 1, as well as to increase its stability, solubility, and cellular permeability. The X-
ray structure of a di-styryl-BODIPY 3b was obtained, showing the planarity and symmetry 
of the BODIPY core, and the E configurations of the styryl groups. The extension of π-
conjugation in BODIPY 1 produced 59–125 nm red-shifts in the absorption and emission 
bands of the mono-styryl- and 126–220 nm in the di-styryl-BODIPYs in DMSO. The 
indolylstyryl- and pyrrolylstyryl-BODIPYs decomposed upon light exposure, even when 
substituted with electron-withdrawing groups (-NO2, -CO2Et); on the other hand the 
tri(ethylene glycol)phenyl- and thienyl-styryl-BODIPYs were stable under similar light 
conditions. The mono-styryl-2,6-diiodo-BODIPYs were found to produce ROS in murine 
hepatoma cells and to display high phototoxicity (IC50 < 15 µM at 1.5 J/cm2) toward HEp2 
cells. The lower symmetry of the mono-styryl-BODIPYs and their preferential localization 
within cell ER and mitochondria may favor their binding to intracellular proteins, such as 
the anti-apoptotic Bcl-2 found in these organelles. On the other hand, the distyryl-2,6-
diiodo-BODIPYs did not produce ROS in cells and had low or no phototoxicity (IC50 > 100 
µM at 1.5 J/cm2). Among this series of compounds, BODIPYs 2a–e show the most promise 
for application as photosensitizers in PDT, while 3a–e are promising near-IR fluorescent 
imaging agents. Among these, BODIPY 2a was found to strongly absorb at λmax 636 nm in 
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DMSO, with high extinction coefficient (∼ 29,000 M−1.cm−1), about 10-fold higher than 
Photofrin®, it was the most phototoxic among the BODIPYs investigated (IC50 = 2 µM at 1 
J/cm2 with a dark/phototoxicity ratio of 74), probably as a result of efficient ROS generation 
within cells, and is therefore particularly promising as a PDT photosensitizer. On the other 
hand, BODIPY 3b shows near-IR emission at λmax 695 nm in DMSO, with fluorescence 
quantum yield of Φf = 0.2 despite the 2,6-diiodo groups that favor intersystem crossing, and 
therefore is a promising near-IR imaging agent.
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Refer to Web version on PubMed Central for supplementary material.
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• A series of mono- and di-styryl-diiodo-BODIPYs were synthesized and 
investigated
• The mono-styryl-diiodo-BODIPYs were found to be phototoxic to HEp2 cells 
and are promising photosensitizers for PDT
• The di-styryl-diiodo-BODIPYs were not phototoxic to HEP2 cells and are 
promising near-IR fluorophores for bioimaging
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Molecular structures of BODIPYs 1 and one of the four independent molecules of 3b, from 
X-ray crystal structure determinations. Ellipsoids are drawn at the 50% probability level.
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Normalized absorption of BODIPYs 1 (hollow triangle, solid line), 2a ( full triangle, solid 
line), 2b (hollow circle, solid line), 2c (full circle, solid line), 2d (hollow square, solid line), 
2e (full square, solid line), 3a (full triangle, dash line), 3b (hollow circle, dash line), 3c (full 
circle, dash line), 3d (hollow square, dash line), and 3e (full square, dash line) in DMSO at 
room temperature.
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Phototoxicity (1.5 J/cm2) of BODIPYs 2a (full square, solid line), 2b (full down triangle, 
solid line), 2c (hollow square, solid line), 2d (full star, solid line), 2e (hollow up triangle, 
solid line), 3a (full up triangle, dash line), 3b (full diamond, dash line), 3c (hollow circle, 
dash line), 3d (full hexagon, dash line), and 3e (full circle, dash line) at 10 µM by HEp2 
cells.
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AFP and DADB fluorescence in control (dark) vs. irradiated 1c1c7 cells: effects of 
BODIPYs 2a and 3a. These results reflect formation of •OH (APF) as indicated by increased 
fluorescence, and of 1O2 as detected by DADB (decreased fluorescence). These results 
represent the results of a typical experiment.
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Time-dependent cellular uptake of BODIPYs 2a (full square, solid line), 2b (full down 
triangle, solid line), 2c (hollow square, solid line), 2d (full star, solid line), 2e (hollow up 
triangle, solid line), 3a (full up triangle, dash line), 3b (full diamond, dash line), 3c (hollow 
circle, dash line), 3d (full hexagon, dash line), and 3e (full circle, dash line) at 10 µM by 
HEp2 cells
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Subcellular localization of BODIPY 2a in HEp2 cells at 10 µM for 6 h. a) Phase contrast, b) 
2a fluorescence, c) ER tracker blue/white fluorescence, e) MitoTracker green fluorescence, 
g) BODIPY Ceramide, i) LysoSensor green fluorescence, and d), f), h), and j) overlays of 
organelle tracers with the BODIPY fluorescence. Scale bar: 10 µm.
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Subcellular localization of BODIPY 2b in HEp2 cells at 10 µM for 6 h. a) Phase contrast, b) 
2b fluorescence, c) ER tracker blue/white fluorescence, e) MitoTracker green fluorescence, 
g) BODIPY Ceramide, i) LysoSensor green fluorescence, and d), f), h), and j) overlays of 
organelle tracers with the BODIPY fluorescence. Scale bar: 10 µm.
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Subcellular localization of BODIPY 2c in HEp2 cells at 10 µM for 6 h. a) Phase contrast, b) 
2c fluorescence, c) ER tracker blue/white fluorescence, e) MitoTracker green fluorescence, 
g) BODIPY Ceramide, i) LysoSensor green fluorescence, and d), f), h), and j) overlays of 
organelle tracers with the BODIPY fluorescence. Scale bar: 10 µm.
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Subcellular localization of BODIPY 2d in HEp2 cells at 10 µM for 6 h. a) Phase contrast, b) 
2d fluorescence, c) ER tracker blue/white fluorescence, e) MitoTracker green fluorescence, 
g) BODIPY Ceramide, i) LysoSensor green fluorescence, and d), f), h), and j) overlays of 
organelle tracers with the BODIPY fluorescence. Scale bar: 10 µm.
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Subcellular localization of BODIPY 2e in HEp2 cells at 10 µM for 6 h. a) Phase contrast, b) 
2e fluorescence, c) ER tracker blue/white fluorescence, e) MitoTracker green fluorescence, 
g) BODIPY Ceramide, i) LysoSensor green fluorescence, and d), f), h), and j) overlays of 
organelle tracers with the BODIPY fluorescence. Scale bar: 10 µm.
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Subcellular localization of BODIPY 3a in HEp2 cells at 10 µM for 6 h. a) Phase contrast, b) 
3a fluorescence, c) ER tracker blue/white fluorescence, e) MitoTracker green fluorescence, 
g) BODIPY Ceramide, i) LysoSensor green fluorescence, and d), f), h), and j) overlays of 
organelle tracers with the BODIPY fluorescence. Scale bar: 10 µm.
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Knoevenagel condensations of BODIPY 1 with aryl aldehydes.
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Table 2
Cytotoxicity (CellTiter Blue assay, 1.5 J/cm2), comparative singlet oxygen quantum yields (relative to 






2a 148 2.0 0.72 1.04
2b > 400 3.8 0.78 0.72
2c > 400 14.5 0.63 0.73
2d > 400 5.0 0.55 1.50
2e > 400 4.0 0.65 1.10
3a > 400 >100 0.64 1.16
3b > 400 >100 0.65 0.89
3c > 400 >100 0.37 1.01
3d > 400 >100 0.34 1.94
3e > 400 > 100 0.43 1.88
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